top
Please input keywords
OK
Database
News events
Contact us
EN
CN
JP
KR
About us
Introduction
History
Management team
Culture
Social Responsibility
Join us
Antibody Assets
Project Integrum
Antibody discovery platforms
Pipeline
Clinical pipeline
Preclinical pipeline
RenMice
RenMab
RenLite
RenNano
Animal Models
Pharmacology Service
Gene Editing
Collaborations
IR
Stock Information
Financial Reports
Listing Documents
Announcements & Notices
Corporate Governance
Investor Calendar
Email Alert
IR Contact
Home
Collaborations
Collaborations
Advancing innovative drug R&D through partnership
Biocytogen is actively seeking partnerships for Project Integrum-derived antibody assets and RenMice-based antibody discovery platforms. Biocytogen is committed to advancing novel drug R&D to benefit patients as soon as possible.
Collaboration Models
Antibody Out-licensing
Antibody Co-Development
Antibody Transfer
Technology Platform Out-licensing
Various drug modalities
Monoclonal Antibody
Bispecific Antibody
Bispecific ADC
Nanobodie
TCRm Antibody
Cell Therapy
Established partnerships
103
103 therapeutic antibody co-development/out-licensing/transfer agreements
47
47 target-nominated RenMice licensing projects
5
5 pipeline-based co-development
Disclosed Partners
Worldwide antibody assets or platform partners include Gilead, Merck KGaA, Janssen, Xencor, ADC Therapeutics, Neurocrine Biosciences, Radiance Biopharma, RemeGen and BeiGene.
Contact us for antibody assets and platforms partnership opportunities at BD-Licensing@biocytogen.com.
Antibody Discovery Platforms